基质金属蛋白酶在喉癌靶向治疗中的研究进展

王 芳武, 周 学军
海南医学院第一附属医院 海南海口 570102

摘要

目的：喉癌是头颈部常见的恶性肿瘤，喉鳞状细胞癌为其主要病理类型，对患者生命造成严重威胁。喉癌由于解剖位置较为隐蔽，早期症状不明显，所以通常诊断确定时半数以上病患已将近晚期，错过了通过手术等方式治疗的最佳时间段，即使某些患者在早期接受相关手术和放射性治疗，并暂时取得了比较好的局部控制率，但也不能杜绝癌细胞远处转移扩散的可能性。尽管近年来随着医学的快速发展，手术、放化疗、分子靶向治疗等治疗方式不断改善，但患有此类疾病患者的预后仍不尽人意。近年来研究发现基质金属蛋白酶(MMPS)在促进肿瘤生长、血管形成、细胞迁移和肿瘤侵袭等多个环节中都扮演了重要角色，与喉癌的发生发展密切相关，有望成为一个新的喉癌治疗靶点。本文就MMPS的生物学特性、MMPs对喉癌发生发展的作用、MMPs抑制策略作为抗癌靶点三个方面进行综述。

关键词

基质金属蛋白酶；肿瘤；喉癌；细胞外基质；靶向治疗

参考

[1]Lee YT, Tan YJ, Oon CE. Molecular targeted therapy: Treating cancer with specificity[J]. Eur J Pharmacol, 2018, 834(11):188-196.[2]Bassiouni W, Ali MAM, Schulz R. Multifunctional intracellular matrix metalloproteinases: implications in disease[J]. FEBS J, 2021, 288(24):7162-7182.[3]Narula S, Tandon C, Tandon S. Role of Matrix Metalloproteinasesin Degenerative Kidney Disorders. Curr Med Chem. 2018;25(15):1805-1816. PMID: 29210632.[4]Gresele P, Falcinelli E, Sebastiano M, et al. Matrix Metalloproteinases and Platelet Function. Prog Mol Biol Transl Sci. 2017;147:133-165. Epub 2017 Mar 21. PMID: 28413027.[5]Cui N, Hu M, Khalil RA. Biochemical and Biological Attributes of Matrix Metalloproteinases[J]. Prog Mol Biol Transl Sci,2017,147(4):1-73.[6]Shimoda M. Extracellular vesicle-associated MMPs: A modulator of the tissue microenvironment[J]. Adv Clin Chem, 2019, 88(9):35-66.[7]Wang X, Khalil RA. Matrix Metalloproteinases, Vascular Remodeling, and Vascular Disease[J]. Adv Pharmacol, 2018, 81(7):241-330.[8]Scheau C, Badarau IA, Costache R, et al. The Role of Matrix Metalloproteinases in the Epithelial-Mesenchymal Transition of Hepatocellular Carcinoma[J]. Anal Cell Pathol (Amst), 2019, 20(6):9423907.[9]Javadian M, Gharibi T, Shekari N, et al. The role of microRNAs regulating the expression of matrix metalloproteinases (MMPs) in breast cancer development, progression, and metastasis[J]. J Cell Physiol, 2019, 234(5):5399-5412.[10]Grzelczyk WL, Wróbel-Roztropiński A, Szemraj J, et al. Matrix metalloproteinases (MMPs) and inhibitor of metalloproteinases (TIMP) mRNA and protein expression in laryngeal squamous cell carcinoma[J]. Arch Med Sci, 2019, 15(3):784-791.[11]Liu RR, Li MD, Li T, et al. Matrix metalloproteinase 2 (MMP2) protein expression and laryngeal cancer prognosis: a meta analysis[J]. Int J Clin Exp Med, 2015, 8(2):2261-2266.[12]刘玉东,甄娟,韩晓丽,等.转移相关蛋白 2、锌指转录蛋白与基质金属蛋白酶 9 在喉鳞状细胞癌中的表达及临床意义[J].中国耳鼻咽喉头颈外科,2020,27(09):507-511.[13]Lotfi A, Mohammadi G, Saniee L, et al. Serum Level of Matrix Metalloproteinase-2 and -9 in Patients with Laryngeal Squamous Cell Carcinoma and Clinical Significance[J]. Asian Pac J Cancer Prev, 2015, 16(15):6749-6751.[14]Matulka M, Konopka A, Mroczko B, et al. Expression and Concentration of Matrix Metalloproteinase 9 and Tissue Inhibitor of Matrix Metalloproteinases 1 in Laryngeal Squamous Cell Carcinoma. Dis Markers. 2019 Apr 18;2019:3136792.[15]Tsiropoulos G, Papadas T, Triantaphyllidou Ie, et al. Pre-treatment gelatinases' serum levels and post-treatment changes in laryngeal cancer patients[J]. Hippokratia, 2013, 17(3):220-227.[16]Quintero-Fabián S, Arreola R, Becerril-Villanueva E, et al. Role of Matrix Metalloproteinases in Angiogenesis and Cancer. Front Oncol, 2019, 9(4):1370-1391.[17]Melincovici CS, Bo ş ca AB, Ş u ş man S, et al. Vascular endothelial growth factor (VEGF) - key factor in normal and pathological angiogenesis[J]. Rom J Morphol Embryol, 2018, 59(2):455-467.[18]Myasoedova VA, Chistiakov DA, Grechko AV, et al. Matrix metalloproteinases in pro-atherosclerotic arterial remodeling. J Mol Cell Cardiol. 2018 Oct;123:159-167.[19]Liu Y, Zhang H, Yan L, et al. MMP-2 and MMP-9 contribute to the angiogenic effect produced by hypoxia/15-HETE in pulmonary endothelial cells[J]. J Mol Cell Cardiol,2018,121(11):36-50.[20]Li H, Lu S, Chen Y, et al. AKT2 phosphorylation of hexokinase 2 at T473 promotes tumorigenesis and metastasis in colon cancer cells via NF-κB, HIF1α, MMP2, and MMP9 upregulation. Cell Signal. 2019 Jun;58:99-110.[21]林雁,尹芳,袁莹,等.基质金属蛋白酶-2和血管内皮生长因子在喉癌中的表达及意义[J].重庆医学,2014,43(16):1972-1974.[22]杨雪,冯志星,彭丽娜,等.喉癌组织中MMP-2和VEGF的表达与转移相关性的研究[J].广西医科大学学报,2021,38(10):1917-1920.[23]周凌智,张本斯,鲁雪静,等.促红细胞生成素产生肝细胞受体A2、肝配蛋白 A1 在乳腺癌组织的表达及意义[J].中华实验外科杂志,2021,38(04):615-619.[24]Ma TT, Wang L, Wang JL, et al. Hypoxia-Induced Cleavage Of Soluble ephrinA1 From Cancer Cells Is Mediated By MMP-2 And Associates With Angiogenesis In Oral Squamous Cell Carcinoma[J]. Onco Targets Ther, 2019, 12(10):8491-8499.[25]Gensbittel V, Kräter M, Harlepp S, et al. Mechanical Adaptability of Tumor Cells in Metastasis[J]. Dev Cell, 2021, 56(2):164-179.[26]Bakir B, Chiarella AM, Pitarresi JR, et al. EMT, MET, Plasticity, and Tumor Metastasis[J]. Trends Cell Biol, 2020, 30(10):764-776.[27]Pastushenko I, Blanpain C. EMT Transition States during Tumor Progression and Metastasis[J]. Trends Cell Biol, 2019, 29(3):212-226.[28]Peters F, Becker-Pauly C. Role of meprin metalloproteases in metastasis and tumor microenvironment[J]. Cancer Metastasis Rev, 2019, 38(3):347-356.[29]吴筱蔓,周兴星,顾翔,等.LC3、MMP-14 及 PD-1 在喉癌中的表 达 及 与 病 理 特 征 和 预 后 的 相 关 性 [J]. 西部医学,2021,33(12):1787-1792.[30]陈建良,鲁慧文,蒋志云,等.PTEN、TIMP-1 及 XIAP 在老年喉癌癌前病变中的表达及临床意义[J].解放军医药杂志,2021,33(12):6-9+29.[31]Matulka M, Konopka A, Mroczko B, et al. Expression and Concentration of Matrix Metalloproteinase 9 and Tissue Inhibitor of Matrix Metalloproteinases 1 in Laryngeal Squamous Cell Carcinoma. Dis Markers. 2019 Apr 18;2019:3136792.[32]Behrends M, Wagner S, Kopka K, et al. New matrix metalloproteinase inhibitors based on γ-fluorinated α-aminocarboxylic and α-aminohydroxamic acids[J]. Bioorg Med Chem, 2015, 23(13):3809-3818.[33]Lv Y, Zhao X, Zhu L, et al. Targeting intracellular MMPs efficiently inhibits tumor metastasis and angiogenesis[J]. Theranostics, 2018, 8(10):2830-2845.[34]Gonzalez-Avila G, Sommer B, García-Hernández AA, et al. Matrix Metalloproteinases' Role in Tumor Microenvironment[J]. Adv Exp Med Biol, 2020, 1245:97-131.[35]Juchniewicz A, Kowalczuk O, Milewski R, et al. MMP-10, MMP-7, TIMP-1 and TIMP-2 mRNA expression in esophageal cancer. Acta Biochim Pol. 2017;64(2):295-299.[36]Stanciu AE, Zamfir-Chiru-Anton A, Stanciu MM, et al. Imbalance between Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases Promotes Invasion and Metastasis of Head and Neck Squamous Cell Carcinoma. Clin Lab. 2017 Oct 1;63(10):1613-1620.[37]Pietruszewska W, Bojanowska-Poźniak K, Kobos J. Matrix metalloproteinases MMP1, MMP2, MMP9 and their tissue inhibitors TIMP1, TIMP2, TIMP3 in head and neck cancer: an immunohistochemical study[J]. Otolaryngol Pol, 2016, 70(3):32-43.